Novo Nordisk axes experimental obesity drugs after success with later-stage meds

After seeing later stage trials come through in obesity, Novo Nordisk is canning two projects that were aiming to help reduce patients’ weight.

Specifically, the Danish drugmaker has terminated its phase 1 GG-co-agonist (a glucagon-GLP-1 co-agonist) and tri-agonist projects (a triple full agonist of the native human GLP-1, gastric inhibitory peptide and glucagon receptors), both of which were designed to treat obesity.